BioLineRx Ltd. — Regulatory Filings 2023

Jun 23, 2023

6-K 1 zk2329906.htm 6-K Licensed to: company Document created using Broadridge PROfile 23.5.1.5152 Copyright 1995 - 2023 Broadridge

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2023

Commission file number: 001-35223

---

BioLineRx Ltd.

(Translation of registrant’s name into English)

---

2 HaMa’ayan Street Modi’in 7177871, Israel

(Address of Principal Executive Offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

The Registrant announces that it will hold an Annual Meeting of Shareholders on August 7, 2023, at 3:00 p.m. (Israel time) at the Registrant’s office, Modi’in Technology Park, 2 HaMa’ayan Street, Modi’in 7177871, Israel. Attached hereto as Exhibit 1 , Exhibit 2 and Exhibit 3 , are, respectively, the Notice of Annual General Meeting and Proxy Statement, Proxy Card and Voting Instruction Card for holders of American Depositary Shares.

This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioLineRx Ltd.
By:	/s/ Philip A. Serlin
	Philip A. Serlin
	Chief Executive Officer

Dated: June 23, 2023